New diagnostic definition outperforms BMI in diagnosing obesity
A new diagnostic definition of obesity outperforms body mass index (BMI) in identifying differences in health and prognosis, including mortality risk, according to a large international study led by researchers from King's College London, UK.
The research tested the diagnostic framework, ‘Definition and diagnostic criteria of clinical obesity’, proposed by a Lancet Diabetes & Endocrinology Commission in January 2025, to address worldwide concerns that reliance on BMI alone may be causing millions of people to be misdiagnosed. The new definition was designed to improve identification of excess body fat and distinguishes clinical from preclinical obesity based on its impact on organ function and daily activities.

"This study shows that up to a third of all cases of obesity are clinical obesity, an active disease that should be treated as such,” said Professor Francesco Rubino, senior author of the study and chair of metabolic and bariatric surgery at King's College London and honorary consultant surgeon at King's College Hospital. "Most people with preclinical obesity, but not all, remained free of clinical obesity for a decade. Preclinical obesity should therefore be neither treated automatically as active disease nor dismissed as harmless. Some people may need preventive treatment, but its intensity should match their individual risk."
BMI does not accurately reflect an individual's body-fat amount or distribution, which strongly influence health risks. It also does not measure effects on organ function and so cannot distinguish illness from health.
The Lancet Commission's diagnostic framework involves two steps:
Complementing BMI with measures such as waist circumference and waist-to-height ratio to confirm excess body fat
Distinguishing clinical obesity, an active disease in which excess body fat impairs organ function, from preclinical obesity, where excess body fat poses increased health risks but organ and whole-body function remain preserved.
The researchers analysed health data from 844,108 adults in China, the UK, the US and Spain, comparing BMI-based classification with the new diagnostic framework. To distinguish organ dysfunction attributable to obesity from conditions that arise from other causes, the study used a statistical method to account for the background risk of organ dysfunction among people without obesity.
Adding waist measurements to standard BMI assessments showed that BMI alone misclassified obesity in both directions - missing obesity-level body fat in up to 8.6% of participants and inadequately classifying up to 3.1% of people as having obesity across the study groups. Obesity was linked to a higher risk of death only when identified using waist measurements alongside BMI - not when using BMI alone.
Clinical obesity accounted for 23%–31% of all obesity cases, had an overall population prevalence of 5.6%–10.9% and was associated with a substantially higher risk of death, while preclinical obesity carried only a modest increase in risk. Most people with preclinical obesity, 77%–91% across cohorts, did not progress to clinical obesity over ten years.
"Body mass index alone cannot tell us whether someone is already ill or at risk of illness, or what care they need, leaving people vulnerable to both undertreatment and overtreatment. The new definition makes personalised, proportionate care possible whereas a uniform BMI-based definition prevents it,” added Rubino. "Getting the scope of care right - treating existing disease or reducing risk - and matching its intensity to individual needs matters enormously, both for the billion-plus people affected and for health care systems. People with obesity, like everyone else, deserve care matched to their needs: no less, and no more."
The research was undertaken in collaboration with Huazhong University of Science and Technology, Kailuan General Hospital and North China University of Science and Technology in China; Pennington Biomedical Research Center and the University of Colorado Anschutz in the United States; the University of Girona in Spain; and Università Cattolica del Sacro Cuore in Italy.
"Rapid advances in treatment make a clinically meaningful diagnosis increasingly important to guide proportionate care,” added Professor An Pan, first author of the study, from Huazhong University of Science and Technology in Wuhan, China. “The marked differences in prognosis between clinical and preclinical obesity, consistently observed across countries and ethnic groups, support global adoption of the new framework to improve obesity care and policy worldwide."
By moving beyond a uniform BMI-based definition, the new framework could help resolve one of medicine's most polarizing debates, shifting the question from whether obesity is a disease to when it constitutes disease in an individual.
The findings were reported in the paper, ‘Validation of clinical and preclinical obesity across global cohorts’, Nature. To access this paper, please click here




Comments